Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Acticor Biotech" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Acticor Biotech for you to read. Along with our medical data and news we also list Acticor Biotech Clinical Trials, which are updated daily. BioPortfolio also has a large database of Acticor Biotech Companies for you to search.
Acticor Biotech SAS (mAb therapeutics to treat ischemic stroke) completed a €1.7mm ($2mm) undisclosed round from Primer Cap...
Ischemic stroke-focused start-up Acticor Biotech SAS (developing a monoclonal antibody with antiplatelet activity) raised €...
Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombo-embolic diseases, including stroke and pulmonary embolism, today announced the appointment of Dr Andrea Comenducci MD as Medical Director in charge of clinical R&D and medical affairs. Dr Comenducci specialises in the cardiovascular field, and his priority ...
Acticor Biotech SAS (antibody therapeutics for acute thrombotic diseases, including ischemic stroke and pulmonary embolism) c...
Biotronik said the Acticor and Rivacor systems are designed to incorporate more diagnostic and therapeutic capabilities in smaller devices with extended battery longevity. The six new tachycardia solutions The post Biotronik secures FDA approval for Acticor and Rivacor CRM device families appeared first on Compelo Medical Devices - Latest industry news and analysis.
Acticor Biotech SAS (MAb therapeutics to treat ischemic stroke) completed an undisclosed €1.4mm ($1.55mm) capital increase ...
New financing will enable the company to launch shortly the first Phase II clinical trial of its lead candidate ACT017 inhibiting GPVI in acute ischemic stroke Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, today announced that it has completed a €15...
The FDA has granted Biotronik premarket approval for its Rivacor and Acticor families of high-voltage cardiac rhythm-managem -More-
SummaryActicor Biotech SAS Acticor, a subsidiary of MabDesign is a biopharmaceutical company that develops innovative therapeutic strategy for the emergency treatment of ischemic strokes. The company provides Fab product that provides monoclonal antibody targeting solutions through platelet glycoprotein VI, which is a protein cloned in the INSERM unit U1148. Its Fab finds application in the area o...
With a massive €530M ($604M) raised, US-based Moderna has made a record biotech IPO. The news could give a significant boost to developers of messenger RNA, a technology that is still several years away from the market. Entering the Nasdaq ... The post What Does the Largest Biotech IPO Ever Mean for European Biotech? appeared first on Labiotech.eu.
Bei BB Biotech (WKN: A0NFN3) war es diese Woche so weit! Die Generalversammlung tagte und hat - so wie wir derzeit lesen können - alles durchgewinkt, was das Management der auf Biotech-Perlen spezi...
Ian Nicholson, CEO of F2G, updated Mike Ward during Biotech Showcase 2019 on the progress the biotech company is having...
Oslo, 13 September 2018. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and ...
Joe Dupere, CEO at Rexgenero, reveals to Mike Ward during Biotech Showcase 2019 the four-year-old UK biotech’s plans.
FIT Biotech Oy Company release 7.1.2019 at 9:55 EET Changes in FIT Biotech’s Board of Directors FIT Biotech Oy’s (“Company”, FITBIO: FN Finland) Chairman of the Board of Directors, Doctor Chitra Bharucha has resigned from Board of Directors for medical reasons. … Continue reading →
Over the last two weeks, several biotech companies in Europe have decided to postpone IPOs on the stock markets — is this a sign that biotech stocks are underperforming? Since the end of October, several European biotech companies have ... The post Are Recent IPO Delays Bad News for European Biotech? appeared first on Labiotech.eu.
As Sweden’s capital, Stockholm is perhaps best known for its picturesque islands and bridges, crayfish festivals, and wondrously preserved medieval architecture, but the city is also a hub of biotech enterprise. Stockholm’s biotech industry is particularly strong when it comes ... The post The Top 10 Biotech Companies in Stockholm appeared first on Labiotech.eu.
Scientists at the University of California at Davis are developing biotech cattle that do not grow horns and biotech cows tha -More-
Early stage biotech companies and scientists interested in commercialization need great accelerator programs, not more biotech incubators. Biotech companies and scientists who start out on the road to commercialization may need an accelerator to bring out the entrepreneurial spirit. The incubator and accelerator models are conflated all the time in biotech, much to the fury […] The post Acce...
Is the next big idea in oncology a bust? What does "successful" mean, exactly? And why does Wall Street hate biotech all of a sudden? Find out on our biotech…
Last year was a remarkable year for biotech companies going public. Not only did an unusually large number of biotech companies go public, but a significant number of early-stage biotech companies went public at premium valuations relative to their later-clinical stage peers. There were approximately 58 biotech IPOs in 2018 (excluding offerings with under $25 […]
There’s just one week left until Xconomy’s latest biotech event, “San Francisco Biotech: The Next Generation.” Don’t let the clock run out while you can still save some cash on a ticket. Next Wednesday, Dec. 5, company founders and visionary scientists will share how they are pursuing new ideas and breaking biotech boundaries. Don’t wait […]
A STAT-curated preview of biotech events and issues that we believe will grab headlines and attention in biotech over the next 12 months.
While major biotech indices went south in 2018, VC enthusiasm for biotech remained bullish. Biotech companies raised a record $22.83bn...